The latest update pegs Pacific Biosciences of California’s fair value at US$2.50 per share, compared with the prior US$2.42 anchor, giving investors a fresh reference point for the story. Analysts are ...

Some tech companies may perform better than others as valuations continue to grow. We may see a pivot from who can build the most to who can utilize the most in AI. Some sectors may still be ...

Amid an earnings season marked by market and economic uncertainty, stocks have seen fewer fair value estimate increases on average than in previous quarters. Even so, some stocks saw their estimates ...

I rated Alphabet as a "Buy" in November due to undervaluation and a strong economic moat, but I trimmed my position after crossing my Fair Value estimate. Despite a slight earnings miss, Alphabet's ...

A prior post — Statutory LLC Buyouts – “Fair Value” vs. “Fair Market Value” — covered an unpublished opinion filed in 2021 addressing the difference between the statutory buyout processes governing ...

Amid a strong quarter of earnings results, Morningstar analysts have been bumping up their fair value estimates for a wide range of stocks. The list of names with the largest fair value increases is ...